{"id":621,"date":"2015-02-10T22:56:55","date_gmt":"2015-02-10T21:56:55","guid":{"rendered":"https:\/\/blogdelarechercheclinique.com\/?p=621"},"modified":"2025-05-21T10:53:35","modified_gmt":"2025-05-21T08:53:35","slug":"mr-001-explications","status":"publish","type":"post","link":"https:\/\/blogdelarechercheclinique.com\/en\/mr-001-explications\/","title":{"rendered":"The MR-001, what is it and how to respect it?"},"content":{"rendered":"<h1 style=\"text-align: justify;\"><em>The<strong> MR-001, what is it and how to respect it?<\/strong><\/em><\/h1>\n<p style=\"text-align: justify;\">As CRA, we are concerned with the application of the MR-001 or Reference Methodology. The MR-001 is a procedure used to simplify the reporting of data processing, in clinical trials, to the National Commission for Data Protection and Liberties (CNIL). Here we will explain what studies are involved and how to respect the MR001? Here are some answers.<\/p>\n<p><!--more--><\/p>\n<p style=\"text-align: justify;\">The MR-001 is used to group in a single file, the statement of data processing, for all the tests performed by a promoter. Thanks to this simplified procedure, you will have a regulatory submission in less to achieve since you will not have to make a complete submission to the CNIL even CCTIRS (this is already something gained \ud83d\ude09 ). Your promoter will simply ensure that he agrees with the said methodology and provide proof\u00a0in case of CNIL inspection.<\/p>\n<div id=\"attachment_623\" style=\"width: 310px\" class=\"wp-caption alignnone\"><a href=\"https:\/\/i0.wp.com\/blogdelarechercheclinique.com\/wp-content\/uploads\/2015\/02\/0008552597P-1920x1280-Copie.jpg\"><img data-recalc-dims=\"1\" decoding=\"async\" aria-describedby=\"caption-attachment-623\" class=\"size-medium wp-image-623 lazyload\" data-src=\"https:\/\/i0.wp.com\/blogdelarechercheclinique.com\/wp-content\/uploads\/2015\/02\/0008552597P-1920x1280-Copie-300x200.jpg?resize=300%2C200\" alt=\"Pour tout savoir sur la MR-001 en un clic ! \" width=\"300\" height=\"200\" src=\"data:image\/svg+xml;base64,PHN2ZyB3aWR0aD0iMSIgaGVpZ2h0PSIxIiB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciPjwvc3ZnPg==\" style=\"--smush-placeholder-width: 300px; --smush-placeholder-aspect-ratio: 300\/200;\" \/><\/a><p id=\"caption-attachment-623\" class=\"wp-caption-text\">To know everything about the MR-001 at once\u00a0!<\/p><\/div>\n<ol>\n<li>\n<h2 style=\"text-align: justify;\"><strong><u>Who is concerned?<\/u><\/strong><\/h2>\n<\/li>\n<\/ol>\n<ul>\n<li style=\"text-align: justify;\"><strong>Non-interventional researches<\/strong>: Not concerned<\/li>\n<li style=\"text-align: justify;\"><strong>Researches to evaluate the routine care: <\/strong>Not concerned<strong>\u00a0<\/strong><\/li>\n<li style=\"text-align: justify;\"><strong>Biomedical research: <\/strong>They are concerned with the MR-001 <u>BUT<\/u> these trials must meet a number of criteria to comply with this methodology.<strong>\u00a0<\/strong><br \/>\nThere is no restriction to the purpose of the study. Your trial may cover a drug, medical device, cosmetic or tattoo or be out of health products.<\/li>\n<li style=\"text-align: justify;\"><strong>The Temporary Recommendations for<\/strong> <strong>Use<\/strong> (TRU) and <strong>Temporary<\/strong> <strong>Authorizations of Use<\/strong> (TAU). Not concerned.<br \/>\nHowever, since January 2015, the TRU and TAU also have a unique authorization: The unique authorization AU-041. For more information, you can visit the CNIL website\u00a0<a href=\"https:\/\/www.cnil.fr\/fr\/actualites\" target=\"_blank\" rel=\"noopener noreferrer\">here<\/a>.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><span style=\"line-height: 1.714285714; font-size: 1rem;\"><strong>Practically in your CRA work<\/strong>: As CRA, in charge of\u00a0regulatory submissions, you have to ensure that the study complies with the MR-001. If the study is consistent with the MR-001, make sure that the promoter has already provided a commitment complying with the MR-001 to the CNIL . This commitment applies to all studies conducted by the promoter.<br \/>\n<\/span>Otherwise, the promoter will have to go on the CNIL website to achieve this compliance commitment. Tell it to your project manager or to your promoter!<\/p>\n<ol style=\"text-align: justify;\" start=\"2\">\n<li>\n<h2><strong><u>How to respect it?<\/u><\/strong><\/h2>\n<\/li>\n<\/ol>\n<p style=\"text-align: justify;\">The MR-001 covers several aspects of the trial:<\/p>\n<ul>\n<li style=\"text-align: justify;\">Information of patients on the fate of their data,<\/li>\n<li style=\"text-align: justify;\">Information of investigators and other research participants (pharmacist, CET, radiologists&#8230;) on the fate of their data (especially when you collect their CVs)<\/li>\n<li style=\"text-align: justify;\">The collection of the patient&rsquo;s consent,<\/li>\n<li style=\"text-align: justify;\">The data collected,<\/li>\n<li style=\"text-align: justify;\">Data processing,<\/li>\n<li style=\"text-align: justify;\">Data analysis,<\/li>\n<li style=\"text-align: justify;\">People with access to data,<\/li>\n<li style=\"text-align: justify;\">Conversations duration,<\/li>\n<li style=\"text-align: justify;\">\u00a0Treatment Security,<\/li>\n<li style=\"text-align: justify;\">The data transfer abroad.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">Here are some points with which\u00a0you should pay attention.<\/p>\n<ul style=\"text-align: justify;\">\n<li>\n<h4><strong>Particular<\/strong> <strong>data: ethnicity and race, sex life, genetic data<\/strong><\/h4>\n<\/li>\n<\/ul>\n<p>Often international promoters require the collection of the patients ethnicity data. Indeed, it has been shown that certain groups of the population respond more or less well to treatment based on their ethnicity.<\/p>\n<p>However, according to the Data Protection Act of 6 January 1978 in France:<br \/>\n\u00ab\u00a0<em>It is forbidden to collect or process personal data that reveal, directly or indirectly, poeple<u>\u00a0racial or ethnic origins<\/u>, political, philosophical or religious opinions or trade union membership, or which relate <u>to the health or sexual life<\/u> of these.<\/em> \u00a0\u00bb<\/p>\n<p>However, the said Act and the MR-001 allow the collection of such data if they are relevant in the light of the research.<\/p>\n<p style=\"text-align: justify;\">Thus, the promoter may collect ethnicity or race data concerning sex life or genetic changes in patients. However, such data collection objectif must be specified in the study protocol and the patient must give his informed consent for the collection of such data.<\/p>\n<p style=\"text-align: justify;\"><strong>Practically in your CRA work<\/strong>: Upon regulatory submission to the CPP (Institutional Review Board), I advise you to read your CRF. If you notice that this type of data is requested, tell\u00a0this to\u00a0the study promoter or with your project manager: does he have a scientific reason to\u00a0collect this data? If so, ask him to state it clearly in the protocol or prepare a letter clarifying that information for your submission to the Ethics Committee\u00a0(otherwise. The Ethics Committee may ask you this later). If the collection of such data is not justified, this information cannot be collected in France and the center will not have the right to complete this field in the CRF. So you will have to look after it.<\/p>\n<ul style=\"text-align: justify;\">\n<li><strong>The information note and informed consent form<\/strong><\/li>\n<\/ul>\n<p style=\"text-align: justify;\">Patients should be informed and give their informed consent to participate in biomedical research. The information given by the investigator to the patient must be summarized in the information note given to the patient. The MR-001 also advocates to state on the information note everything concerning the processing of patients personal data.<\/p>\n<p style=\"text-align: justify;\"><strong>In practice in your CRA work<\/strong>: you must indicate in your informed consent: the nature of the transmitted data (e.g.: ethnicity, sex life &#8230;), the purpose of the data processing, natural or legal persons recipients of the data (the promoter, the Competent Authorities, &#8230;), the existence of the access right, rectification, and opposition<strong>,<\/strong> the possible inclusion in the national register of the person participating in the research (in case of research on healthy volunteers or patients with pathology unrelated to the product studied), &#8230; You will find ready-made phrases in the MR-001, you will simply adapt them to your study and that&rsquo;s it\u00a0\ud83d\ude09<\/p>\n<p>Beware, if your study requires the collection and processing of genetic data, a specific consent must be obtained from the patient.<\/p>\n<ul style=\"text-align: justify;\">\n<li><strong>Data from other participants in the research (investigators, CET&#8230;)<\/strong><\/li>\n<\/ul>\n<p style=\"text-align: justify;\">Research participants data are anonymous. However, the data that is collected\u00a0for other participants (investigators, CET, Pharmacist&#8230;) are generally registered (especially when you collect CVs).<\/p>\n<p style=\"text-align: justify;\"><strong>Practically in your CRA work:<\/strong> Other participants must then also be informed of the processing of their personal data. This information should be on:<\/p>\n<p style=\"text-align: justify;\">&#8211;\u00a0The agreement signed with the investigator or,<\/p>\n<p style=\"text-align: justify;\">&#8211; A document given to investigators and others participants that will preferably be signed by the concerned person.<\/p>\n<ul style=\"text-align: justify;\">\n<li>\n<h4><strong>In case of data transfer abroad<\/strong><\/h4>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">In case of international study, data about your patients, investigators and others will not stay\u00a0in France. These data will probably be transferred to companies located in other countries in Europe or countries out of the European Union. Beware, the transfer I am speaking to here, concerns any company through which the data passes by: it can be your promoter, but also a subcontractor for data entry, for example.<\/p>\n<p style=\"text-align: justify;\">The identified data transfer of your patients is allowed. However, the patient should be informed of the data transfer outside the European Union in his Informed consent.<br \/>\nHowever, you should know that the transfer of personal data identifiers outside the EU are prohibited (This applies to data included in the CV of your investigators and other professionals, for example). Except in the following case:<\/p>\n<ul style=\"text-align: justify;\">\n<li>If the data transfer takes place to a country considered as\u00a0\u00bbproviding an adequate level of data protection.\u00a0\u00bb You will find an interactive map on the website of the CNIL <a href=\"http:\/\/www.cnil.fr\/linstitution\/international\/les-autorites-de-controle-dans-le-monde\/\" target=\"_blank\" rel=\"noopener noreferrer\">here<\/a>.<\/li>\n<\/ul>\n<ul style=\"text-align: justify;\">\n<li>If standard contractual clauses were signed between the two companies (a company in France and a subcontractor abroad for example). This is a contract signed by the two companies that fixes the responsibilities of every\u00a0part. The contract must be approved by the European Commission. You can find a standard contract <a href=\"http:\/\/www.cnil.fr\/vos-obligations\/transfert-de-donnees-hors-ue\/contrats-types-de-la-commission-europeenne\/\" target=\"_blank\" rel=\"noopener noreferrer\">here<\/a>.<\/li>\n<\/ul>\n<ul style=\"text-align: justify;\">\n<li>If your promoter adopted Internal Corporate Rules (Biding Corporate Rules BCR). This is a code of conduct in data transfer matters abroad adopted within a group (your promoter and his subsidiaries).<\/li>\n<\/ul>\n<p><strong>In your CRA work<\/strong>: You have to check if your promoter has adopted one of these measures. In this case, it is not necessary to make an application to the CNIL. Otherwise, you will have to make one for the transfer of such data or suggest\u00a0any of these solutions to the promoter (Safe Harbor, Contractual Clauses Types, and BCR).<\/p>\n<p style=\"text-align: justify;\">Beware, if your sponsor is not based in the EU, he must appoint a legal representative established in the European Community under Article\u00a0\u00a0<a href=\"http:\/\/www.legifrance.gouv.fr\/affichCodeArticle.do?idArticle=LEGIARTI000006685827&amp;cidTexte=LEGITEXT000006072665&amp;dateTexte=20080129\" target=\"_blank\" rel=\"noopener noreferrer\">L1121-1 of the Code of Public Health<\/a>.\u00a0This legal representative must respect the French regulation.<br \/>\nTO sum up, the data of the persons ready for the\u00a0research and other participants (investigators, CET, Pharmacists) must be protected both during data processing, and during their transfer or archiving. Individuals must be informed of the processing of their data and must consent to this processing, either on a contract or on a specific document explaining the fate of their data.<\/p>\n<p style=\"text-align: justify;\">I hope this little abrigement\u00a0could enlighten you on the MR-001.<\/p>\n<p style=\"text-align: justify;\">For more information, you can visit the website below:<\/p>\n<ul style=\"text-align: justify;\">\n<li>For the conformity declaration with the MR-001: <a href=\"http:\/\/www.cnil.fr\/vos-obligations\/declarer-a-la-cnil\/\">http:\/\/www.cnil.fr\/vos-obligations\/declarer-a-la-cnil\/<\/a><\/li>\n<\/ul>\n<p style=\"text-align: justify;\">Also, visit Pharmaspecific website : \u00a0<a href=\"http:\/\/www.pharmaspecific.fr\/\" target=\"_blank\" rel=\"noopener noreferrer\">http:\/\/www.pharmaspecific.fr<\/a>\u00a0and discover our activities.<\/p>\n<p style=\"text-align: justify;\">If you liked this article, I invite you to click on \u00ab\u00a0I like\u00a0\u00bb or share with your CRA colleagues and friends and project Manager.<\/p>\n<p>Also, visit Pharmaspecific website : \u00a0<a href=\"http:\/\/www.pharmaspecific.fr\/\">http:\/\/www.pharmaspecific.fr<\/a>\u00a0and discover our activities.<\/p>\n<p>You can visit the Facebook page of \u00ab\u00a0blog de la recherche clinique\u00a0\u00bb\u00a0and the\u00a0\u00ab\u00a0Pharmaspecific\u00a0\u00bb\u00a0and click on \u00ab\u00a0I like\u00a0\u00bb to support us.<\/p>\n<p>See\u00a0\u00ab\u00a0<a href=\"https:\/\/www.linkedin.com\/company\/pharmaspecific\/\">Pharmaspecific Linkedin<\/a>\u00a0\u00bb\u00a0and\u00a0\u00ab\u00a0<a href=\"https:\/\/www.linkedin.com\/in\/vanessamontanari\/\">Vanessa Montanari Linkedin<\/a>\u00a0\u00bb \u00a0on\u00a0LinkedIn for more relevant news on clinical researches.<\/p>\n<p>You can also subscribe on the blog&rsquo;s newsletter we will keep you posted once a new article is published.<\/p>","protected":false},"excerpt":{"rendered":"<p>Article r\u00e9dig\u00e9 par la Soci\u00e9t\u00e9 Pharmaspecific, sp\u00e9cialiste en recherche clinique La MR-001, qu\u2019est-ce que c\u2019est et comment la&#8230;<\/p>","protected":false},"author":4,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"om_disable_all_campaigns":false,"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":{"facebook_122143508198123560_331463380343150":""},"rop_publish_now_history":[],"rop_publish_now_status":"pending","_sitemap_exclude":false,"_sitemap_priority":"","_sitemap_frequency":"","_exactmetrics_skip_tracking":false,"_exactmetrics_sitenote_active":false,"_exactmetrics_sitenote_note":"","_exactmetrics_sitenote_category":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":""},"categories":[450],"tags":[16,66,145,136,137,146,139,147],"class_list":{"0":"post-621","1":"post","2":"type-post","3":"status-publish","4":"format-standard","6":"category-actualites-de-la-recherche-clinique","7":"tag-arc","8":"tag-attache-de-recherche-clinique","9":"tag-cnil","10":"tag-consentement","11":"tag-consentement-eclaire","12":"tag-mr-001","13":"tag-note-dinformation","14":"tag-soumission-reglementaire"},"translation":{"provider":"WPGlobus","version":"3.0.2","language":"en","enabled_languages":["fr","en"],"languages":{"fr":{"title":true,"content":true,"excerpt":false},"en":{"title":true,"content":true,"excerpt":false}}},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>The MR-001, what is it and how to respect it?<\/title>\n<meta name=\"description\" content=\"As CRA, we are concerned with the application of the MR-001 or Reference Methodology. The MR-001 is a procedure used to simplify the reporting.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/blogdelarechercheclinique.com\/en\/mr-001-explications\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"The MR-001, what is it and how to respect it?\" \/>\n<meta property=\"og:description\" content=\"As CRA, we are concerned with the application of the MR-001 or Reference Methodology. The MR-001 is a procedure used to simplify the reporting.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/blogdelarechercheclinique.com\/en\/mr-001-explications\/\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/blogdelarechercheclinique\" \/>\n<meta property=\"article:published_time\" content=\"2015-02-10T21:56:55+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-05-21T08:53:35+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/blogdelarechercheclinique.com\/wp-content\/uploads\/2015\/02\/0008552597P-1920x1280-Copie-300x200.jpg\" \/>\n<meta name=\"author\" content=\"Vanessa Montanari\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Vanessa Montanari\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"18 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/blogdelarechercheclinique.com\/mr-001-explications\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/blogdelarechercheclinique.com\/mr-001-explications\/\"},\"author\":{\"name\":\"Vanessa Montanari\",\"@id\":\"https:\/\/blogdelarechercheclinique.com\/#\/schema\/person\/13ee3f7a1251afe7e98918a482685938\"},\"headline\":\"The MR-001, what is it and how to respect it?\",\"datePublished\":\"2015-02-10T21:56:55+00:00\",\"dateModified\":\"2025-05-21T08:53:35+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/blogdelarechercheclinique.com\/mr-001-explications\/\"},\"wordCount\":3570,\"commentCount\":1,\"publisher\":{\"@id\":\"https:\/\/blogdelarechercheclinique.com\/#organization\"},\"image\":{\"@id\":\"https:\/\/blogdelarechercheclinique.com\/mr-001-explications\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/blogdelarechercheclinique.com\/wp-content\/uploads\/2015\/02\/0008552597P-1920x1280-Copie-300x200.jpg\",\"keywords\":[\"ARC\",\"Attach\u00e9 de recherche clinique\",\"CNIL\",\"Consentement\",\"Consentement \u00e9clair\u00e9\",\"MR-001\",\"Note d'information\",\"soumission r\u00e8glementaire\"],\"articleSection\":[\"Actualit\u00e9s de la recherche clinique\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/blogdelarechercheclinique.com\/mr-001-explications\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/blogdelarechercheclinique.com\/mr-001-explications\/\",\"url\":\"https:\/\/blogdelarechercheclinique.com\/mr-001-explications\/\",\"name\":\"The MR-001, what is it and how to respect it? -\",\"isPartOf\":{\"@id\":\"https:\/\/blogdelarechercheclinique.com\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/blogdelarechercheclinique.com\/mr-001-explications\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/blogdelarechercheclinique.com\/mr-001-explications\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/blogdelarechercheclinique.com\/wp-content\/uploads\/2015\/02\/0008552597P-1920x1280-Copie-300x200.jpg\",\"datePublished\":\"2015-02-10T21:56:55+00:00\",\"dateModified\":\"2025-05-21T08:53:35+00:00\",\"description\":\"En tant qu\u2019ARC, nous sommes concern\u00e9s par l\u2019application de la MR-001, une proc\u00e9dure servant \u00e0 simplifier la d\u00e9claration du traitement des donn\u00e9es \u00e0 la CNIL.\",\"breadcrumb\":{\"@id\":\"https:\/\/blogdelarechercheclinique.com\/mr-001-explications\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/blogdelarechercheclinique.com\/mr-001-explications\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/blogdelarechercheclinique.com\/mr-001-explications\/#primaryimage\",\"url\":\"https:\/\/blogdelarechercheclinique.com\/wp-content\/uploads\/2015\/02\/0008552597P-1920x1280-Copie-300x200.jpg\",\"contentUrl\":\"https:\/\/blogdelarechercheclinique.com\/wp-content\/uploads\/2015\/02\/0008552597P-1920x1280-Copie-300x200.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/blogdelarechercheclinique.com\/mr-001-explications\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\/\/blogdelarechercheclinique.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"La MR-001, qu\u2019est-ce que c\u2019est et comment la respecter ?\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/blogdelarechercheclinique.com\/#website\",\"url\":\"https:\/\/blogdelarechercheclinique.com\/\",\"name\":\"Blog de la recherche clinique\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/blogdelarechercheclinique.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/blogdelarechercheclinique.com\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/blogdelarechercheclinique.com\/#organization\",\"name\":\"Blog de la recherche clinique\",\"url\":\"https:\/\/blogdelarechercheclinique.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/blogdelarechercheclinique.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/i0.wp.com\/blogdelarechercheclinique.com\/blog-contenu\/uploads\/2024\/04\/cropped-BLOG-logo.png?fit=512%2C512&ssl=1\",\"contentUrl\":\"https:\/\/i0.wp.com\/blogdelarechercheclinique.com\/blog-contenu\/uploads\/2024\/04\/cropped-BLOG-logo.png?fit=512%2C512&ssl=1\",\"width\":512,\"height\":512,\"caption\":\"Blog de la recherche clinique\"},\"image\":{\"@id\":\"https:\/\/blogdelarechercheclinique.com\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/blogdelarechercheclinique\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/blogdelarechercheclinique.com\/#\/schema\/person\/13ee3f7a1251afe7e98918a482685938\",\"name\":\"Vanessa Montanari\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/blogdelarechercheclinique.com\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/ddf428208f542d6c2239ace6606ebe9beb71049642a9c784967f23e4e76e8efc?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/ddf428208f542d6c2239ace6606ebe9beb71049642a9c784967f23e4e76e8efc?s=96&d=mm&r=g\",\"caption\":\"Vanessa Montanari\"},\"url\":\"https:\/\/blogdelarechercheclinique.com\/en\/author\/vanessa\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"The MR-001, what is it and how to respect it?","description":"As CRA, we are concerned with the application of the MR-001 or Reference Methodology. The MR-001 is a procedure used to simplify the reporting.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/blogdelarechercheclinique.com\/en\/mr-001-explications\/","og_locale":"en_US","og_type":"article","og_title":"The MR-001, what is it and how to respect it?","og_description":"As CRA, we are concerned with the application of the MR-001 or Reference Methodology. The MR-001 is a procedure used to simplify the reporting.","og_url":"https:\/\/blogdelarechercheclinique.com\/en\/mr-001-explications\/","article_publisher":"https:\/\/www.facebook.com\/blogdelarechercheclinique","article_published_time":"2015-02-10T21:56:55+00:00","article_modified_time":"2025-05-21T08:53:35+00:00","og_image":[{"url":"https:\/\/blogdelarechercheclinique.com\/wp-content\/uploads\/2015\/02\/0008552597P-1920x1280-Copie-300x200.jpg","type":"","width":"","height":""}],"author":"Vanessa Montanari","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Vanessa Montanari","Est. reading time":"18 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/blogdelarechercheclinique.com\/mr-001-explications\/#article","isPartOf":{"@id":"https:\/\/blogdelarechercheclinique.com\/mr-001-explications\/"},"author":{"name":"Vanessa Montanari","@id":"https:\/\/blogdelarechercheclinique.com\/#\/schema\/person\/13ee3f7a1251afe7e98918a482685938"},"headline":"The MR-001, what is it and how to respect it?","datePublished":"2015-02-10T21:56:55+00:00","dateModified":"2025-05-21T08:53:35+00:00","mainEntityOfPage":{"@id":"https:\/\/blogdelarechercheclinique.com\/mr-001-explications\/"},"wordCount":3570,"commentCount":1,"publisher":{"@id":"https:\/\/blogdelarechercheclinique.com\/#organization"},"image":{"@id":"https:\/\/blogdelarechercheclinique.com\/mr-001-explications\/#primaryimage"},"thumbnailUrl":"https:\/\/blogdelarechercheclinique.com\/wp-content\/uploads\/2015\/02\/0008552597P-1920x1280-Copie-300x200.jpg","keywords":["ARC","Attach\u00e9 de recherche clinique","CNIL","Consentement","Consentement \u00e9clair\u00e9","MR-001","Note d'information","soumission r\u00e8glementaire"],"articleSection":["Actualit\u00e9s de la recherche clinique"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/blogdelarechercheclinique.com\/mr-001-explications\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/blogdelarechercheclinique.com\/mr-001-explications\/","url":"https:\/\/blogdelarechercheclinique.com\/mr-001-explications\/","name":"The MR-001, what is it and how to respect it? -","isPartOf":{"@id":"https:\/\/blogdelarechercheclinique.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/blogdelarechercheclinique.com\/mr-001-explications\/#primaryimage"},"image":{"@id":"https:\/\/blogdelarechercheclinique.com\/mr-001-explications\/#primaryimage"},"thumbnailUrl":"https:\/\/blogdelarechercheclinique.com\/wp-content\/uploads\/2015\/02\/0008552597P-1920x1280-Copie-300x200.jpg","datePublished":"2015-02-10T21:56:55+00:00","dateModified":"2025-05-21T08:53:35+00:00","description":"En tant qu\u2019ARC, nous sommes concern\u00e9s par l\u2019application de la MR-001, une proc\u00e9dure servant \u00e0 simplifier la d\u00e9claration du traitement des donn\u00e9es \u00e0 la CNIL.","breadcrumb":{"@id":"https:\/\/blogdelarechercheclinique.com\/mr-001-explications\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/blogdelarechercheclinique.com\/mr-001-explications\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/blogdelarechercheclinique.com\/mr-001-explications\/#primaryimage","url":"https:\/\/blogdelarechercheclinique.com\/wp-content\/uploads\/2015\/02\/0008552597P-1920x1280-Copie-300x200.jpg","contentUrl":"https:\/\/blogdelarechercheclinique.com\/wp-content\/uploads\/2015\/02\/0008552597P-1920x1280-Copie-300x200.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/blogdelarechercheclinique.com\/mr-001-explications\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/blogdelarechercheclinique.com\/"},{"@type":"ListItem","position":2,"name":"La MR-001, qu\u2019est-ce que c\u2019est et comment la respecter ?"}]},{"@type":"WebSite","@id":"https:\/\/blogdelarechercheclinique.com\/#website","url":"https:\/\/blogdelarechercheclinique.com\/","name":"Blog de la recherche clinique","description":"","publisher":{"@id":"https:\/\/blogdelarechercheclinique.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/blogdelarechercheclinique.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/blogdelarechercheclinique.com\/#organization","name":"Blog de la recherche clinique","url":"https:\/\/blogdelarechercheclinique.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/blogdelarechercheclinique.com\/#\/schema\/logo\/image\/","url":"https:\/\/i0.wp.com\/blogdelarechercheclinique.com\/blog-contenu\/uploads\/2024\/04\/cropped-BLOG-logo.png?fit=512%2C512&ssl=1","contentUrl":"https:\/\/i0.wp.com\/blogdelarechercheclinique.com\/blog-contenu\/uploads\/2024\/04\/cropped-BLOG-logo.png?fit=512%2C512&ssl=1","width":512,"height":512,"caption":"Blog de la recherche clinique"},"image":{"@id":"https:\/\/blogdelarechercheclinique.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/blogdelarechercheclinique"]},{"@type":"Person","@id":"https:\/\/blogdelarechercheclinique.com\/#\/schema\/person\/13ee3f7a1251afe7e98918a482685938","name":"Vanessa Montanari","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/blogdelarechercheclinique.com\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/ddf428208f542d6c2239ace6606ebe9beb71049642a9c784967f23e4e76e8efc?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/ddf428208f542d6c2239ace6606ebe9beb71049642a9c784967f23e4e76e8efc?s=96&d=mm&r=g","caption":"Vanessa Montanari"},"url":"https:\/\/blogdelarechercheclinique.com\/en\/author\/vanessa\/"}]}},"jetpack_featured_media_url":"","jetpack-related-posts":[{"id":3817,"url":"https:\/\/blogdelarechercheclinique.com\/en\/jamais-2-3-apres-mr-002-voici-mr-003\/","url_meta":{"origin":621,"position":0},"title":"En quoi consiste la nouvelle m\u00e9thodologie de recherche MR-003","author":"Vanessa Montanari","date":"20 April 2017","format":false,"excerpt":"Article r\u00e9dig\u00e9 par la Soci\u00e9t\u00e9 Pharmaspecific, sp\u00e9cialiste en recherche clinique Et nous souhaitons la bienvenue \u00e0 \u2026 la nouvelle m\u00e9thodologie de r\u00e9f\u00e9rence MR-003\u00a0! En effet, le 14 ao\u00fbt 2016, le Journal Officiel a publi\u00e9 la d\u00e9lib\u00e9ration n\u00b02016-263 du 21 juillet 2016 portant sur l\u2019homologation d'une m\u00e9thodologie de r\u00e9f\u00e9rence relative aux\u2026","rel":"","context":"In &quot;Les r\u00e8glementaires&quot;","block_context":{"text":"Les r\u00e8glementaires","link":"https:\/\/blogdelarechercheclinique.com\/en\/category\/reglementaires\/"},"img":{"alt_text":"","src":"","width":0,"height":0},"classes":[]},{"id":13926,"url":"https:\/\/blogdelarechercheclinique.com\/en\/mr-002-nouvelle-methode-reference-recherche-clinique\/","url_meta":{"origin":621,"position":1},"title":"MR-002 : la nouvelle m\u00e9thode de r\u00e9f\u00e9rence en recherche clinique","author":"Vanessa Montanari","date":"11 November 2015","format":false,"excerpt":"Une nouvelle m\u00e9thodologie de r\u00e9f\u00e9rence, la MR-002, a \u00e9t\u00e9 cr\u00e9\u00e9e\u00a0? Elle a \u00e9t\u00e9 publi\u00e9e au Journal Officiel le 22 ao\u00fbt dernier. Dans cet article nous allons t\u2019expliquer en quoi elle consiste.","rel":"","context":"In &quot;Les r\u00e8glementaires&quot;","block_context":{"text":"Les r\u00e8glementaires","link":"https:\/\/blogdelarechercheclinique.com\/en\/category\/reglementaires\/"},"img":{"alt_text":"Nouvelle m\u00e9thode de r\u00e9f\u00e9rence","src":"https:\/\/i0.wp.com\/blogdelarechercheclinique.com\/blog-contenu\/uploads\/2015\/11\/Encadrement-MR002.png?fit=851%2C565&ssl=1&resize=350%2C200","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/blogdelarechercheclinique.com\/blog-contenu\/uploads\/2015\/11\/Encadrement-MR002.png?fit=851%2C565&ssl=1&resize=350%2C200 1x, https:\/\/i0.wp.com\/blogdelarechercheclinique.com\/blog-contenu\/uploads\/2015\/11\/Encadrement-MR002.png?fit=851%2C565&ssl=1&resize=525%2C300 1.5x, https:\/\/i0.wp.com\/blogdelarechercheclinique.com\/blog-contenu\/uploads\/2015\/11\/Encadrement-MR002.png?fit=851%2C565&ssl=1&resize=700%2C400 2x"},"classes":[]},{"id":13931,"url":"https:\/\/blogdelarechercheclinique.com\/en\/safe-harbor-transfert-donnees-personnelles\/","url_meta":{"origin":621,"position":2},"title":"Safe Harbor : transfert de donn\u00e9es personnelles non valid\u00e9","author":"Vanessa Montanari","date":"4 November 2015","format":false,"excerpt":"Savais tu que l\u2019accord commercial reliant l\u2019Espace Economique Europ\u00e9en et les Etats-Unis avait \u00e9t\u00e9 invalid\u00e9 et que les transferts de donn\u00e9es personnelles r\u00e9alis\u00e9s dans le cadre du Safe Harbor n\u2019\u00e9taient plus autoris\u00e9s ? Voici concr\u00e8tement ce que cela implique pour tes essais.","rel":"","context":"In &quot;Les r\u00e8glementaires&quot;","block_context":{"text":"Les r\u00e8glementaires","link":"https:\/\/blogdelarechercheclinique.com\/en\/category\/reglementaires\/"},"img":{"alt_text":"Invalidation safe harbor","src":"https:\/\/i0.wp.com\/blogdelarechercheclinique.com\/blog-contenu\/uploads\/2024\/05\/safe-harbor.jpg?resize=350%2C200&ssl=1","width":350,"height":200},"classes":[]},{"id":14895,"url":"https:\/\/blogdelarechercheclinique.com\/en\/quelle-destinee-pour-la-recherche-clinique-2-0\/","url_meta":{"origin":621,"position":3},"title":"Quelle destin\u00e9e pour la recherche clinique 2.0 ?","author":"Vanessa Montanari","date":"21 September 2024","format":false,"excerpt":"R\u00e9dig\u00e9 par l'\u00e9quipe de Pharmaspecific. Introduction Ces derni\u00e8res ann\u00e9es, la technologie a r\u00e9volutionn\u00e9 presque tous les aspects de notre vie et la recherche clinique ne fait pas exception. Avec l\u2019av\u00e8nement de nouvelles technologies et l\u2019\u00e9volution constante des r\u00e9glementations, le r\u00f4le des Attach\u00e9s de Recherche Clinique (ARC)\u00a0 et Techniciens d\u2019\u00e9tude clinique\u2026","rel":"","context":"In &quot;Actualit\u00e9s de la recherche clinique&quot;","block_context":{"text":"Actualit\u00e9s de la recherche clinique","link":"https:\/\/blogdelarechercheclinique.com\/en\/category\/actualites-de-la-recherche-clinique\/"},"img":{"alt_text":"R\u00e9ussir un entretien t\u00e9l\u00e9phonique est donc la premi\u00e8re \u00e9tape vers le succ\u00e8s.","src":"https:\/\/i0.wp.com\/blogdelarechercheclinique.com\/blog-contenu\/uploads\/2015\/08\/entretien-telephonique.png?fit=986%2C657&ssl=1&resize=350%2C200","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/blogdelarechercheclinique.com\/blog-contenu\/uploads\/2015\/08\/entretien-telephonique.png?fit=986%2C657&ssl=1&resize=350%2C200 1x, https:\/\/i0.wp.com\/blogdelarechercheclinique.com\/blog-contenu\/uploads\/2015\/08\/entretien-telephonique.png?fit=986%2C657&ssl=1&resize=525%2C300 1.5x, https:\/\/i0.wp.com\/blogdelarechercheclinique.com\/blog-contenu\/uploads\/2015\/08\/entretien-telephonique.png?fit=986%2C657&ssl=1&resize=700%2C400 2x"},"classes":[]},{"id":13922,"url":"https:\/\/blogdelarechercheclinique.com\/en\/mr-002-clinical-research\/","url_meta":{"origin":621,"position":4},"title":"After the MR-001, the MR-002&#8230; procession statement biomedical research","author":"Vanessa Montanari","date":"11 November 2015","format":false,"excerpt":"In a previous blog post that you can find here, we told you about the RM-001, procedure simplifying the data processing statement during biomedical research at the CNIL-France (National Commission for Data Protection and Liberties).","rel":"","context":"In &quot;Les r\u00e8glementaires&quot;","block_context":{"text":"Les r\u00e8glementaires","link":"https:\/\/blogdelarechercheclinique.com\/en\/category\/reglementaires\/"},"img":{"alt_text":"MR002: nouvelle m\u00e9thodologie de r\u00e9f\u00e9rence","src":"https:\/\/i0.wp.com\/blogdelarechercheclinique.com\/blog-contenu\/uploads\/2024\/05\/MR002.png?fit=738%2C656&ssl=1&resize=350%2C200","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/blogdelarechercheclinique.com\/blog-contenu\/uploads\/2024\/05\/MR002.png?fit=738%2C656&ssl=1&resize=350%2C200 1x, https:\/\/i0.wp.com\/blogdelarechercheclinique.com\/blog-contenu\/uploads\/2024\/05\/MR002.png?fit=738%2C656&ssl=1&resize=525%2C300 1.5x, https:\/\/i0.wp.com\/blogdelarechercheclinique.com\/blog-contenu\/uploads\/2024\/05\/MR002.png?fit=738%2C656&ssl=1&resize=700%2C400 2x"},"classes":[]},{"id":6194,"url":"https:\/\/blogdelarechercheclinique.com\/en\/note-information-consentement-eclaire\/","url_meta":{"origin":621,"position":5},"title":"Information note and informed consent, the main points","author":"Vanessa Montanari","date":"16 December 2014","format":false,"excerpt":"{:fr}Article r\u00e9dig\u00e9 par la Soci\u00e9t\u00e9 Pharmaspecific, sp\u00e9cialiste en recherche clinique Note d'information et consentement \u00e9clair\u00e9, les points essentiels. Tu as une note d\u2019information et un formulaire de consentement \u00e0 r\u00e9diger et tu ne sais pas par o\u00f9 commencer\u00a0? Tu as un consentement \u00e0 revoir et tu aimerais conna\u00eetre les points\u2026","rel":"","context":"In &quot;Actualit\u00e9s de la recherche clinique&quot;","block_context":{"text":"Actualit\u00e9s de la recherche clinique","link":"https:\/\/blogdelarechercheclinique.com\/en\/category\/actualites-de-la-recherche-clinique\/"},"img":{"alt_text":"0010556279O-1920x1280","src":"https:\/\/i0.wp.com\/blogdelarechercheclinique.com\/wp-content\/uploads\/2014\/12\/0010556279O-1920x1280-300x200.jpg?resize=350%2C200","width":350,"height":200},"classes":[]}],"jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/blogdelarechercheclinique.com\/en\/wp-json\/wp\/v2\/posts\/621","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/blogdelarechercheclinique.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/blogdelarechercheclinique.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/blogdelarechercheclinique.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/blogdelarechercheclinique.com\/en\/wp-json\/wp\/v2\/comments?post=621"}],"version-history":[{"count":1,"href":"https:\/\/blogdelarechercheclinique.com\/en\/wp-json\/wp\/v2\/posts\/621\/revisions"}],"predecessor-version":[{"id":15293,"href":"https:\/\/blogdelarechercheclinique.com\/en\/wp-json\/wp\/v2\/posts\/621\/revisions\/15293"}],"wp:attachment":[{"href":"https:\/\/blogdelarechercheclinique.com\/en\/wp-json\/wp\/v2\/media?parent=621"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/blogdelarechercheclinique.com\/en\/wp-json\/wp\/v2\/categories?post=621"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/blogdelarechercheclinique.com\/en\/wp-json\/wp\/v2\/tags?post=621"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}